NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023

Area of Science:

• Oncology
• Clinical Guidelines
• Thoracic Surgery

Background:

• Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality.
• Surgical resection is a primary treatment modality for early-stage NSCLC.
• Optimizing systemic therapy in the perioperative setting is crucial for improving survival rates.

Purpose of the Study:

• To summarize the NCCN Guidelines for perioperative systemic therapy in resectable NSCLC.
• To provide evidence-based recommendations for neoadjuvant and adjuvant treatment strategies.
• To inform clinical decision-making for oncologists and surgeons managing NSCLC.

Main Methods:

• Review and synthesis of current NCCN Guidelines.
• Focus on systemic therapy options (chemotherapy, immunotherapy, targeted therapy).
• Consideration of patient eligibility and disease characteristics for perioperative treatment.

Main Results:

• NCCN Guidelines provide specific recommendations for neoadjuvant and adjuvant systemic therapy.
• Perioperative therapy aims to reduce recurrence and improve overall survival in resectable NSCLC.
• Treatment selection depends on NSCLC subtype, stage, and patient factors.

Conclusions:

• Perioperative systemic therapy represents a significant advancement in the management of resectable NSCLC.
• Adherence to NCCN Guidelines ensures optimal and evidence-based treatment selection.
• Further research is ongoing to refine and expand perioperative treatment options for NSCLC.